<DOC>
	<DOC>NCT01764594</DOC>
	<brief_summary>To evaluate safety, tolerability pharmacokinetics and immunogenicity of CDP7657.</brief_summary>
	<brief_title>Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Immune System Diseases</mesh_term>
	<mesh_term>Connective Tissue Diseases</mesh_term>
	<criteria>Patients with Systemic Lupus Erythematosus (SLE) Severe neuropsychiatric or severe renal Systemic Lupus Erythematosus (SLE) History of chronic, recurrent, or recent severe infection Significant hematologic abnormalities History of cancer, heart failure, renal disease, liver disease or other serious illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Lupus</keyword>
	<keyword>SLE</keyword>
</DOC>